Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 28 points (-0.2%) at 17,094 as of Thursday, Aug. 28, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,204 issues advancing vs. 1,745 declining with 194 unchanged.

The Health Care sector currently sits down 0.3% versus the S&P 500, which is down 0.1%. Top gainers within the sector include

Centene

(

CNC

), up 2.8%,

Aetna

(

AET

), up 0.8%,

Bristol-Myers Squibb Company

(

BMY

), up 0.7% and

Humana

(

HUM

), up 0.5%. On the negative front, top decliners within the sector include

Grifols

(

GRFS

), down 1.2%,

Sanofi

(

SNY

), down 1.1%,

Express Scripts

(

ESRX

), down 1.0%,

Baxter International

(

BAX

), down 0.7% and

Alexion Pharmaceuticals

(

ALXN

), down 0.6%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3.

Isis Pharmaceuticals

(

ISIS

) is one of the companies pushing the Health Care sector higher today. As of noon trading, Isis Pharmaceuticals is up $1.66 (4.2%) to $41.24 on heavy volume. Thus far, 2.0 million shares of Isis Pharmaceuticals exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $39.13-$42.14 after having opened the day at $39.14 as compared to the previous trading day's close of $39.58.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Isis Pharmaceuticals, Inc. is engaged in the discovery and development of antisense drugs using novel drug discovery platform. Isis Pharmaceuticals has a market cap of $4.7 billion and is part of the drugs industry. Shares are down 0.7% year-to-date as of the close of trading on Wednesday. Currently there are 4 analysts who rate Isis Pharmaceuticals a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Isis Pharmaceuticals

as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full

Isis Pharmaceuticals Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading,

AstraZeneca

(

AZN

) is up $0.66 (0.9%) to $74.21 on light volume. Thus far, 847,344 shares of AstraZeneca exchanged hands as compared to its average daily volume of 2.7 million shares. The stock has ranged in price between $73.76-$74.28 after having opened the day at $73.78 as compared to the previous trading day's close of $73.55.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. AstraZeneca has a market cap of $93.1 billion and is part of the drugs industry. Shares are up 23.9% year-to-date as of the close of trading on Wednesday. Currently there is 1 analyst who rates AstraZeneca a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates

AstraZeneca

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

AstraZeneca Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading,

Amgen

(

AMGN

) is up $1.02 (0.7%) to $138.85 on average volume. Thus far, 1.4 million shares of Amgen exchanged hands as compared to its average daily volume of 2.9 million shares. The stock has ranged in price between $137.29-$139.38 after having opened the day at $137.65 as compared to the previous trading day's close of $137.83.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Amgen has a market cap of $104.3 billion and is part of the drugs industry. Shares are up 20.8% year-to-date as of the close of trading on Wednesday. Currently there are 7 analysts who rate Amgen a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates

Amgen

as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, revenue growth, reasonable valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

Amgen Ratings Report

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).

null